Medicinal Chemistry Profiling of Monocyclic 1,2-Azaborines

ChemMedChem. 2017 Mar 7;12(5):358-361. doi: 10.1002/cmdc.201700047. Epub 2017 Feb 21.

Abstract

The first examples of biologically active monocyclic 1,2-azaborines have been synthesized and demonstrated to exhibit not only improved in vitro aqueous solubility in comparison with their corresponding carbonaceous analogues, but in the context of a CDK2 inhibitor, also improved biological activity and better in vivo oral bioavailability. This proof-of-concept study establishes the viability of monocyclic 1,2-azaborines as a novel pharmacophore with distinct pharmacological profiles that can help address challenges associated with solubility in drug development research.

Keywords: BN heterocycle; CDK2 inhibitors; azaborines; drug discovery; solubility.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Administration, Oral
  • Animals
  • Binding Sites
  • Boron Compounds / chemistry*
  • Boron Compounds / metabolism
  • Boron Compounds / pharmacokinetics
  • Chemistry, Pharmaceutical
  • Cyclin-Dependent Kinase 2 / antagonists & inhibitors*
  • Cyclin-Dependent Kinase 2 / metabolism
  • Half-Life
  • Hydrogen Bonding
  • Male
  • Molecular Dynamics Simulation
  • Protein Kinase Inhibitors / chemistry*
  • Protein Kinase Inhibitors / metabolism
  • Protein Structure, Tertiary
  • Rats
  • Rats, Sprague-Dawley
  • Solubility

Substances

  • 1,2-azaborine
  • Boron Compounds
  • Protein Kinase Inhibitors
  • Cyclin-Dependent Kinase 2